- CFO Spotlights
- Profiles
- Matthew Gall
Profile
Matthew Gall
Chief Financial Officer (Principal Financial Officer), Kalaris Therapeutics, Inc.
A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.
Matthew Gall signed the annual report of Kalaris Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer), filed March 17, 2026.1 A later filing by Kalaris Therapeutics, Inc., made on July 20, 2026, names Liisa Bayko as its chief financial officer; the record holds no filing that reports the end of Matthew Gall's tenure.
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) Biological Products, (No Diagnostic Substances) | Chief Financial Officer (Principal Financial Officer) | A later filing names a successor Liisa Bayko, filed July 20, 2026 (filing) |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- March 17, 202610-K filed
Matthew Gall signed the annual report of Kalaris Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer), filed March 17, 2026.
/s/ Matthew Gall Chief Financial Officer March 17, 2026 Matthew Gall (Principal Financial Officer)
[1] Annual report on Form 10-K by Kalaris Therapeutics, Inc., filed with the SEC on March 17, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Annual report on Form 10-K, Kalaris Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 17, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Matthew Gall wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.